StockMacro
Menu

AbCellera Biologics

$9.69 +83% in 6 monthsMarket cap $3.2B

ABCL on XNAS, Health Care, AbCellera Biologics Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 184% in 12 months while the company lost $148.3M despite revenue up 92%.

  • GoodInsiders bought $1.4M of shares in 90 days, sold nothing

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Industry
Pharmaceutical preparations (Health Care)
Employees
562
Website
abcellera.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 23 Feb 2027 (an estimate: a year ago it reported on 24 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $10.6M, net loss $40.8M.
Quarter to 31 Dec 2021: revenue –, net income $59.9MQuarter to 31 Mar 2022: revenue $316.6M, net income $168.6MQuarter to 31 Mar 2022: revenue $316.6M, net income $168.6MQuarter to 30 Jun 2022: revenue $45.9M, net income -$6.8MQuarter to 30 Jun 2022: revenue $45.9M, net income -$6.8MQuarter to 30 Sep 2022: revenue $101.4M, net income $26.6MQuarter to 30 Sep 2022: revenue $101.4M, net income $26.6MQuarter to 31 Dec 2022: revenue $21.5M, net income -$29.9MQuarter to 31 Dec 2022: revenue $21.5M, net income -$29.9MQuarter to 31 Mar 2023: revenue $12.2M, net income -$40.1MQuarter to 31 Mar 2023: revenue $12.2M, net income -$40.1MQuarter to 30 Jun 2023: revenue $10.1M, net income -$30.5MQuarter to 30 Jun 2023: revenue $10.1M, net income -$30.5MQuarter to 30 Sep 2023: revenue $6.6M, net income -$28.6MQuarter to 30 Sep 2023: revenue $6.6M, net income -$28.6MQuarter to 31 Dec 2023: revenue $9.2M, net income -$47.1MQuarter to 31 Dec 2023: revenue $9.2M, net income -$47.1MQuarter to 31 Mar 2024: revenue $10.0M, net income -$40.6MQuarter to 31 Mar 2024: revenue $10.0M, net income -$40.6MQuarter to 30 Jun 2024: revenue $7.3M, net income -$36.9MQuarter to 30 Jun 2024: revenue $7.3M, net income -$36.9MQuarter to 30 Sep 2024: revenue $6.5M, net income -$51.1MQuarter to 30 Sep 2024: revenue $6.5M, net income -$51.1MQuarter to 31 Dec 2024: revenue $5.0M, net income -$34.2MQuarter to 31 Dec 2024: revenue $5.0M, net income -$34.2MQuarter to 31 Mar 2025: revenue $4.2M, net income -$45.6MQuarter to 31 Mar 2025: revenue $4.2M, net income -$45.6MQuarter to 30 Jun 2025: revenue $17.1M, net income -$34.7MQuarter to 30 Jun 2025: revenue $17.1M, net income -$34.7MQuarter to 30 Sep 2025: revenue $9.0M, net income -$57.1MQuarter to 30 Sep 2025: revenue $9.0M, net income -$57.1MQuarter to 31 Dec 2025: revenue –, net income -$8.9MQuarter to 31 Mar 2026: revenue $8.3M, net income -$43.2MQuarter to 31 Mar 2026: revenue $8.3M, net income -$43.2MQuarter to 30 Jun 2026: revenue $4.0M, net income -$55.4MQuarter to 30 Jun 2026: revenue $4.0M, net income -$55.4MQuarter to 30 Sep 2026: revenue $10.6M, net income -$40.8MQuarter to 30 Sep 2026: revenue $10.6M, net income -$40.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $316.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$10.6M-$40.8M
30 Jun 2026$4.0M-$55.4M
31 Mar 2026$8.3M-$43.2M
31 Dec 2025–-$8.9M
30 Sep 2025$9.0M-$57.1M
30 Jun 2025$17.1M-$34.7M
31 Mar 2025$4.2M-$45.6M
31 Dec 2024$5.0M-$34.2M
30 Sep 2024$6.5M-$51.1M
30 Jun 2024$7.3M-$36.9M
31 Mar 2024$10.0M-$40.6M
31 Dec 2023$9.2M-$47.1M
30 Sep 2023$6.6M-$28.6M
30 Jun 2023$10.1M-$30.5M
31 Mar 2023$12.2M-$40.1M
31 Dec 2022$21.5M-$29.9M
30 Sep 2022$101.4M$26.6M
30 Jun 2022$45.9M-$6.8M
31 Mar 2022$316.6M$168.6M
31 Dec 2021–$59.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $67.9M $35.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +92% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$148.3M -$171.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.48 -$0.57
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -298% -740% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -219% -486% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -14.6% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$32.9M -$153.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $764.4M $495.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$764.4M (net cash) -$495.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.25
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 46.6 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 35.4 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
AbCellera BiologicsABCL (this company) $3.2Bloss46.6+92%-219%
Viking TherapeuticsVKTX $3.2Bloss–––
Xeris BiopharmaXERS $3.1Bloss8.4+38%-1.8%
Bausch Health CompaniesBHC $3.1Bloss0.28+11%-7.6%
Arcutis BiotherapeuticsARQT $3.3B1116.6+60%5.9%
Amylyx PharmaceuticalsAMLX $3.3Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$1.4M

bought $1.4M, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.6%

161 13F filers vs 151

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

40%

131.2M shares held by 13F filers (30 Sep 2026) of 326.6M outstanding (4 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.9%

29.0M shares sold short (30 Oct 2026) of 326.6M outstanding (4 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.5

29.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.2%

30.9M shares sold short in the report before, 29.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

32%

32% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

37

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-82%

$1.6M vs $8.9M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

0

0 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

0 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 40, 1.3× a year earlier

Price $9.69 on 20 Nov 2026, +184% over 12 months (12-month range $2.78 to $14.82)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $3.3M in the last 12 months (the 12 months before: $1.1M).
Revenue per quarter. Revenue $10.6M in the latest quarter, +19% on a year earlier.
Capital spending per quarter. Capital spending $1.6M in the latest quarter, -82% on a year earlier.
Institutional holders (13F filers). 161 13F filers reported holding it in the latest 13F quarter, +19% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 40 vs usual 19 (2026-09-30); 1.3x the same period a year earlier
19 Aug 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 975K)
6 Jul 20268-K and other filingsDirector or officer change
5 Jun 20268-K and other filingsDirector or officer change
5 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Feb 2026Sharp changeQuarterly revenue change: quarterly revenue change, 44.9M vs usual 8.1M (2025-12-31); 8.9x the same period a year earlier
28 Nov 20258-K and other filingsChanged its auditor
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 31 vs usual 17.50 (2025-09-30); 1.9x the same period a year earlier
12 Nov 20258-K and other filingsDirector or officer change
12 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 2025Sharp changeShort interest spike: short interest spike, 44.4M vs usual 21.3M (2025-09-15); 2.6x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 43.2M vs usual 20.0M (2025-08-29); 2.5x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 41.8M vs usual 19.2M (2025-08-15); 2.3x the same period a year earlier
12 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 17.1M vs usual 7.0M (2025-06-30); 2.3x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 39.8M vs usual 18.3M (2025-07-31); 2.3x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 35.7M vs usual 18.0M (2025-07-15); 2.0x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 26.5M vs usual 18.0M (2025-06-13); 1.3x the same period a year earlier
23 Feb 20248-K and other filingsDirector or officer change
23 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Nov 2022Sharp changeShort interest spike: short interest spike, 19.5M vs usual 12.0M (2022-10-14); 1.9x the same period a year earlier
18 Oct 2022Sharp changeShort interest spike: short interest spike, 19.4M vs usual 11.9M (2022-09-30); 2.4x the same period a year earlier
27 Sep 2022Sharp changeShort interest spike: short interest spike, 21.6M vs usual 11.8M (2022-09-15); 2.8x the same period a year earlier
13 Sep 2022Sharp changeShort interest spike: short interest spike, 20.1M vs usual 11.6M (2022-08-31); 2.6x the same period a year earlier
30 Aug 2022Sharp changeShort interest spike: short interest spike, 19.3M vs usual 11.3M (2022-08-15); 1.8x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 19.1M vs usual 11.0M (2022-07-29); 2.2x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 19.2M vs usual 10.7M (2022-07-15); 2.3x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 19.2M vs usual 10.6M (2022-06-30); 2.3x the same period a year earlier
18 Jul 20228-K and other filingsDirector or officer change
6 Jul 20228-K and other filingsDirector or officer change
6 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 May 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 13.0M)
17 May 2022Sharp changeQuarterly revenue change: quarterly revenue change, 316.6M vs usual 11.2M (2022-03-31); 1.6x the same period a year earlier
8 Dec 2021Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 5.2M)
7 Dec 20218-K and other filingsDirector or officer change
7 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: $1.2M published
Month from 1 Mar 2022: $2.3M published
Month from 1 May 2022: $13.0M published
Month from 1 Jun 2022: $999K published
Month from 1 Aug 2022: $2.3M published
Month from 1 Dec 2022: $860K published
Month from 1 May 2023: $1.1M published
Month from 1 Aug 2023: $177K published
Month from 1 Sep 2023: $202K published
Month from 1 Nov 2023: $137K published
Month from 1 Aug 2024: $740K published
Month from 1 Mar 2025: $940K published
Month from 1 Nov 2025: $178K published
Month from 1 Feb 2026: $726K published
Month from 1 Mar 2026: $131K published
Month from 1 May 2026: $95K published
Month from 1 Aug 2026: $1.5M published
Month from 1 Nov 2026: $796K published
Revenue per quarter
Quarter ended 31 Dec 2020: $207.9M; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $316.6M, +56% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $45.9M, +66% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $101.4M, +1741% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $21.5M; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $12.2M, -96% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $10.1M, -78% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $6.6M, -93% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $9.2M, -57% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $10.0M, -18% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $7.3M, -27% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $6.5M, -1.4% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $5.0M, -45% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $4.2M, -57% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $17.1M, +133% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $9.0M, +38% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $8.3M, +96% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $4.0M, -76% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $10.6M, +19% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $1.5M; public on 26 Feb 2022
Quarter ended 31 Dec 2021: $9.4M, +528% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $14.5M, +298% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $31.3M, -15% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $12.5M, +46% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $12.3M, +31% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $15.0M, +3.4% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $27.2M, -13% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $20.3M, +62% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $14.4M, +17% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $24.1M, +61% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $20.1M, -26% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $18.5M, -8.9% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $15.6M, +8.3% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $10.6M, -56% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $13.4M, -34% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $8.9M, -52% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $9.8M, -37% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $3.8M, -64% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $2.1M, -84% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $1.6M, -82% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 112; public on 14 Feb 2022
31 Mar 2022 report: 122; public on 16 May 2022
30 Jun 2022 report: 149; public on 15 Aug 2022
30 Sep 2022 report: 175; public on 14 Nov 2022
31 Dec 2022 report: 181; public on 14 Feb 2023
31 Mar 2023 report: 173; public on 15 May 2023
30 Jun 2023 report: 158; public on 14 Aug 2023
30 Sep 2023 report: 127; public on 14 Nov 2023
31 Dec 2023 report: 131; public on 14 Feb 2024
31 Mar 2024 report: 150; public on 15 May 2024
30 Jun 2024 report: 137; public on 14 Aug 2024
30 Sep 2024 report: 132; public on 14 Nov 2024
31 Dec 2024 report: 143; public on 14 Feb 2025
31 Mar 2025 report: 123; public on 15 May 2025
30 Jun 2025 report: 122; public on 14 Aug 2025
30 Sep 2025 report: 135; public on 14 Nov 2025
31 Dec 2025 report: 139; public on 17 Feb 2026
31 Mar 2026 report: 135; public on 15 May 2026
30 Jun 2026 report: 151; public on 14 Aug 2026
30 Sep 2026 report: 161; public on 16 Nov 2026
Federal obligations
Month from 1 Aug 2022: $196K published
Month from 1 Mar 2023: $492K published
Month from 1 Aug 2023: $0 published
Month from 1 Mar 2024: $196K published

What is unusual now

  • Made public in the last 90 days: it saw 40 13F filers open a new position in the quarter ended 30 Sep 2026, 1.3× the same quarter last year.
  • Clustered insider buying: had 3 insiders buy $975K of its shares on the open market within 30 days (3 filings) Public on 19 Aug 2026.
  • Many funds opening a new position: saw 40 13F filers open a new position in the quarter ended 30 Sep 2026, 1.3× the same quarter last year Public on 16 Nov 2026.
  • Revenue per quarter: Revenue $10.6M in the latest quarter, +19% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 49 insider trades

Last 90 days: no sales; 2 purchases, $796K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Nov 2026Andrew BoothChief Financial OfficerBuy8,600$11.33$97KForm 4
12 Nov 2026Thermopylae Holdings Ltd.10% ownerBuy60,565$11.54$699KForm 4
24 Aug 2026Michael R HaydenDirectorBuy53,613$10.64$570KForm 4
18 Aug 2026John S. MontalbanoDirectorBuy10,000$11.03$110KForm 4
14 Aug 2026Andrew BoothChief Financial OfficerBuy37,200$10.32$384KForm 4
14 Aug 2026Michael R HaydenDirectorBuy46,387$10.37$481KForm 4
18 May 2026John S. MontalbanoDirectorBuy20,000$4.77$95KForm 4
2 Mar 2026Thermopylae Holdings Ltd.10% ownerBuy38,000$3.44$131KForm 4

161 institutions reported shares at the end of Q3 2026, 40% of the shares outstanding; 40 opened a position, 30 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Baker Bros. Advisors LP33.0M10.1%$481.6M+10%
Capital World Investors13.6M4.16%$198.1M-9,233-0.1%
Two Sigma Investments, LP11.7M3.58%$170.7M+1.3M+12%
TD Waterhouse Canada Inc.9.2M2.82%$128.3M-346K-3.6%
Marshall Wace, LLP9.0M2.74%$130.7M+7.1M+371%
BlackRock, Inc.5.7M1.73%$82.6M+1.9M+49%
ArrowMark Colorado Holdings LLC4.8M1.48%$70.4M+718K+17%
Bank of America Corp4.2M1.28%$61.0M-2.0M-32%
D. E. Shaw & Co., Inc.3.7M1.12%$53.4M+3.6M81 times as many
Alyeska Investment Group, L.P.3.1M0.94%$44.7M+2.5M+482%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 12 Feb 2018. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
12 Feb 2018Department of the InteriorDepartmental Offices$17.6MD18AC00002GrantUSAspending

Company events

All 19 company events

In 12 months: 2 director or officer changes, 1 auditor change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
13 Aug 2026Signed a major agreement8-K
6 Jul 2026Director or officer change8-K
5 Jun 2026Director or officer change8-K
28 Nov 2025Changed its auditor8-K
12 Nov 2025Director or officer change8-K
23 Feb 2024Director or officer change8-K
24 May 2023Signed a major agreementSame filing: took on new debt8-K
18 Jul 2022Director or officer change8-K

37 open postings; careers site tracked since 20 Nov 2026. Most in Test, quality & reliability 27%, Legal, policy & compliance 24%, Research & science 19%, Operations & administration 14%.

PostedJobLocation
18 Nov 2026Senior Director, Statistical ProgrammingLegal, policy & complianceCalifornia
11 Nov 2026Senior Manager, CMC Regulatory AffairsLegal, policy & complianceCalifornia
9 Nov 2026(Senior) Director, Drug Safety and Pharmacovigilance OperationsOperations & administrationCalifornia
9 Nov 2026Senior CMC Regulatory Affairs ManagerLegal, policy & complianceMontreal
4 Nov 2026Principal Scientist, Clinical PharmacologyResearch & scienceCalifornia
4 Nov 2026Principal Scientist, Clinical PharmacologyResearch & scienceVancouver
26 Oct 2026Senior Clinical ScientistResearch & scienceVancouver
24 Oct 2026Associate Director, Regulatory AffairsLegal, policy & complianceVancouver
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

12 Aug 2025confirmed

Confirmed across sources Filings + Financials and Short interest and volume

AbCellera Biologics (ABCL): reported revenue of $17.1M for the quarter ended 30 Jun 2025, 2.3× the same quarter last year, while it had 39.8M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year. Two unrelated kinds of activity within 63 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2025
  • Financials: Quarterly revenue change, became public on 12 Aug 2025
  • Short interest and volume: Short interest spike, became public on 12 Aug 2025
  • Short interest and volume: Short interest spike, became public on 27 Aug 2025
  • Short interest and volume: Short interest spike, became public on 11 Sep 2025
  • Short interest and volume: Short interest spike, became public on 25 Sep 2025
2023-06-30: $10.1M2023-09-30: $6.6M2023-12-31: $9.2M2024-03-31: $10.0M2024-06-30: $7.3M2024-09-30: $6.5M2024-12-31: $5.0M2025-03-31: $4.2M2025-06-30: $17.1M
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: $7.0M
See the evidence (6 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2025

AbCellera Biologics had 35.7M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

This period
35.7M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
18.0M
Typical spread (median absolute deviation)
1.8M
How far from its usual level
+6.6
Same report last year
17.8M
History used
1,673 days
2024-07-15: 17.8M2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M
the 15 Jul 2025 report24 earlier reportsnormal: 18.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 12 Aug 2025

AbCellera Biologics reported revenue of $17.1M for the quarter ended 30 Jun 2025, 2.3× the same quarter last year.

This period
$17.1M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$7.0M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+3.3
Same quarter last year
$7.3M
History used
1,917 days
2023-06-30: $10.1M2023-09-30: $6.6M2023-12-31: $9.2M2024-03-31: $10.0M2024-06-30: $7.3M2024-09-30: $6.5M2024-12-31: $5.0M2025-03-31: $4.2M2025-06-30: $17.1M
the quarter ended 30 Jun 20258 earlier quartersnormal: $7.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 12 Aug 2025

AbCellera Biologics had 39.8M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year.

This period
39.8M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
18.3M
Typical spread (median absolute deviation)
1.9M
How far from its usual level
+7.5
Same report last year
17.4M
History used
1,689 days
2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M
the 31 Jul 2025 report24 earlier reportsnormal: 18.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Aug 2025

AbCellera Biologics had 41.8M shares sold short in the 15 Aug 2025 report, 2.3× the same report last year.

This period
41.8M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
19.2M
Typical spread (median absolute deviation)
3.1M
How far from its usual level
+5.0
Same report last year
18.2M
History used
1,704 days
2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M
the 15 Aug 2025 report24 earlier reportsnormal: 19.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Sep 2025

AbCellera Biologics had 43.2M shares sold short in the 29 Aug 2025 report, 2.5× the same report last year.

This period
43.2M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
20.0M
Typical spread (median absolute deviation)
3.3M
How far from its usual level
+4.8
Same report last year
17.6M
History used
1,718 days
2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M2025-08-29: 43.2M
the 29 Aug 2025 report24 earlier reportsnormal: 20.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2025

AbCellera Biologics had 44.4M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

This period
44.4M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
21.3M
Typical spread (median absolute deviation)
4.4M
How far from its usual level
+3.6
Same report last year
16.8M
History used
1,735 days
2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M2025-08-29: 43.2M2025-09-15: 44.4M
the 15 Sep 2025 report24 earlier reportsnormal: 21.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

18 May 2022confirmed

Confirmed across sources Insiders and Filings + Financials

AbCellera Biologics (ABCL): reported revenue of $316.6M for the quarter ended 31 Mar 2022, 1.6× the same quarter last year, while it had 3 insiders buy $13.0M of its shares on the open market within 30 days (4 filings). Two unrelated kinds of activity on the same day.

  • Financials: Quarterly revenue change, became public on 17 May 2022
  • Insiders: Clustered insider buying, became public on 18 May 2022
2020-03-31: $4.7M2020-06-30: $11.2M2020-09-30: $9.4M2020-12-31: $207.9M2021-03-31: $202.7M2021-06-30: $27.6M2021-09-30: $5.5M2022-03-31: $316.6M
The quarter ended 31 Mar 2022 against the 7 quarters before it. this quarterearliernormal: $11.2M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 17 May 2022

AbCellera Biologics reported revenue of $316.6M for the quarter ended 31 Mar 2022, 1.6× the same quarter last year.

This period
$316.6M (the quarter ended 31 Mar 2022)
Normal quarter (median of 7 earlier)
$11.2M
Typical spread (median absolute deviation)
$6.6M
How far from its usual level
+31.3
Same quarter last year
$202.7M
History used
730 days
2020-03-31: $4.7M2020-06-30: $11.2M2020-09-30: $9.4M2020-12-31: $207.9M2021-03-31: $202.7M2021-06-30: $27.6M2021-09-30: $5.5M2022-03-31: $316.6M
the quarter ended 31 Mar 20227 earlier quartersnormal: $11.2M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Insiders: Clustered insider buying became public on 18 May 2022

AbCellera Biologics had 3 insiders buy $13.0M of its shares on the open market within 30 days (4 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
4
Total bought
$13.0M
Window
18 Apr 2022 to 18 May 2022

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 40 13F filers open a new position in the quarter ended 30 Sep 2026, 1.3× the same quarter last year.

    Same quarter last year: 31; its normal quarter is 19.

    See the evidence
    This period
    40 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    19
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +3.5
    Same quarter last year
    31
    History used
    2,099 days
    2024-09-30: 162024-12-31: 202025-03-31: 122025-06-30: 182025-09-30: 312025-12-31: 242026-03-31: 182026-06-30: 392026-09-30: 40
    the quarter ended 30 Sep 20268 earlier quartersnormal: 19

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 13 Nov 2026Insiders record

    Booth Andrew (Chief Financial Officer) bought 8,600 shares of ABCL ($97,438)

  3. 12 Nov 2026Insiders record

    Thermopylae Holdings Ltd. (ten percent owner) bought 60,565 shares of ABCL ($698,920)

  4. 25 Aug 2026Insiders record

    Hayden Michael R (director) bought 53,613 shares of ABCL ($570,442) (dated 24 Aug 2026)

  5. 19 Aug 2026Insiders change

    had 3 insiders buy $975K of its shares on the open market within 30 days (3 filings).

    Who bought: Hayden Michael R, Booth Andrew, Montalbano John S..

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $975K
    Window
    20 Jul 2026 to 19 Aug 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  6. 19 Aug 2026Insiders record

    Montalbano John S. (director) bought 10,000 shares of ABCL ($110,300) (dated 18 Aug 2026)

  7. 15 Aug 2026Insiders record

    Booth Andrew (Chief Financial Officer) bought 37,200 shares of ABCL ($383,904) (dated 14 Aug 2026)

  8. 15 Aug 2026Insiders record

    Hayden Michael R (director) bought 46,387 shares of ABCL ($481,033) (dated 14 Aug 2026)

  9. 6 Jul 2026Filings record

    Director or officer change

  10. 5 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 5 Jun 2026Filings record

    Director or officer change

  12. 19 May 2026Insiders record

    Montalbano John S. (director) bought 20,000 shares of ABCL ($95,400) (dated 18 May 2026)

  13. 3 Mar 2026Insiders record

    Thermopylae Holdings Ltd. (ten percent owner) bought 38,000 shares of ABCL ($130,720) (dated 2 Mar 2026)

  14. 28 Feb 2026Insiders record

    Booth Andrew (Chief Financial Officer) bought 42,600 shares of ABCL ($145,692) (dated 27 Feb 2026)

  15. 28 Feb 2026Insiders record

    Thermopylae Holdings Ltd. (ten percent owner) bought 177,457 shares of ABCL ($580,284) (dated 27 Feb 2026)

  16. 26 Feb 2026Financials change

    reported revenue of $44.9M for the quarter ended 31 Dec 2025, 8.9× the same quarter last year.

    Same quarter last year: $5.0M; its normal quarter is $8.1M.

    See the evidence
    This period
    $44.9M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $8.1M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +14.4
    Same quarter last year
    $5.0M
    History used
    2,101 days
    2023-12-31: $9.2M2024-03-31: $10.0M2024-06-30: $7.3M2024-09-30: $6.5M2024-12-31: $5.0M2025-03-31: $4.2M2025-06-30: $17.1M2025-09-30: $9.0M2025-12-31: $44.9M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $8.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 28 Nov 2025Filings record

    Changed its auditor

  18. 27 Nov 2025Insiders record

    Montalbano John S. (director) bought 50,000 shares of ABCL ($178,500) (dated 26 Nov 2025)

  19. 14 Nov 2025Institutional holdings change

    saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 1.9× the same quarter last year.

    Same quarter last year: 16; its normal quarter is 17.5.

    See the evidence
    This period
    31 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    17.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +4.5
    Same quarter last year
    16
    History used
    1,734 days
    2023-09-30: 162023-12-31: 172024-03-31: 262024-06-30: 182024-09-30: 162024-12-31: 202025-03-31: 122025-06-30: 182025-09-30: 31
    the quarter ended 30 Sep 20258 earlier quartersnormal: 17.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  20. 12 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 12 Nov 2025Filings record

    Director or officer change

  22. 25 Sep 2025Short interest and volume change

    had 44.4M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

    Same report last year: 16.8M; its normal report is 21.3M.

    See the evidence
    This period
    44.4M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    21.3M
    Typical spread (median absolute deviation)
    4.4M
    How far from its usual level
    +3.6
    Same report last year
    16.8M
    History used
    1,735 days
    2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M2025-08-29: 43.2M2025-09-15: 44.4M
    the 15 Sep 2025 report24 earlier reportsnormal: 21.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 11 Sep 2025Short interest and volume change

    had 43.2M shares sold short in the 29 Aug 2025 report, 2.5× the same report last year.

    Same report last year: 17.6M; its normal report is 20.0M.

    See the evidence
    This period
    43.2M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    20.0M
    Typical spread (median absolute deviation)
    3.3M
    How far from its usual level
    +4.8
    Same report last year
    17.6M
    History used
    1,718 days
    2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M2025-08-29: 43.2M
    the 29 Aug 2025 report24 earlier reportsnormal: 20.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 27 Aug 2025Short interest and volume change

    had 41.8M shares sold short in the 15 Aug 2025 report, 2.3× the same report last year.

    Same report last year: 18.2M; its normal report is 19.2M.

    See the evidence
    This period
    41.8M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    19.2M
    Typical spread (median absolute deviation)
    3.1M
    How far from its usual level
    +5.0
    Same report last year
    18.2M
    History used
    1,704 days
    2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M
    the 15 Aug 2025 report24 earlier reportsnormal: 19.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 12 Aug 2025several at once

    reported revenue of $17.1M for the quarter ended 30 Jun 2025, 2.3× the same quarter last year, while it had 39.8M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year. Two unrelated kinds of activity within 63 days.

    See the evidence (6 changes)

    Short interest and volume: Short interest spike became public on 25 Jul 2025

    AbCellera Biologics had 35.7M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

    This period
    35.7M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    18.0M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +6.6
    Same report last year
    17.8M
    History used
    1,673 days
    2024-07-15: 17.8M2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M
    the 15 Jul 2025 report24 earlier reportsnormal: 18.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 12 Aug 2025

    AbCellera Biologics reported revenue of $17.1M for the quarter ended 30 Jun 2025, 2.3× the same quarter last year.

    This period
    $17.1M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $7.0M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    +3.3
    Same quarter last year
    $7.3M
    History used
    1,917 days
    2023-06-30: $10.1M2023-09-30: $6.6M2023-12-31: $9.2M2024-03-31: $10.0M2024-06-30: $7.3M2024-09-30: $6.5M2024-12-31: $5.0M2025-03-31: $4.2M2025-06-30: $17.1M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $7.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 12 Aug 2025

    AbCellera Biologics had 39.8M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year.

    This period
    39.8M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    18.3M
    Typical spread (median absolute deviation)
    1.9M
    How far from its usual level
    +7.5
    Same report last year
    17.4M
    History used
    1,689 days
    2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M
    the 31 Jul 2025 report24 earlier reportsnormal: 18.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Aug 2025

    AbCellera Biologics had 41.8M shares sold short in the 15 Aug 2025 report, 2.3× the same report last year.

    This period
    41.8M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    19.2M
    Typical spread (median absolute deviation)
    3.1M
    How far from its usual level
    +5.0
    Same report last year
    18.2M
    History used
    1,704 days
    2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M
    the 15 Aug 2025 report24 earlier reportsnormal: 19.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Sep 2025

    AbCellera Biologics had 43.2M shares sold short in the 29 Aug 2025 report, 2.5× the same report last year.

    This period
    43.2M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    20.0M
    Typical spread (median absolute deviation)
    3.3M
    How far from its usual level
    +4.8
    Same report last year
    17.6M
    History used
    1,718 days
    2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M2025-08-29: 43.2M
    the 29 Aug 2025 report24 earlier reportsnormal: 20.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2025

    AbCellera Biologics had 44.4M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.

    This period
    44.4M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    21.3M
    Typical spread (median absolute deviation)
    4.4M
    How far from its usual level
    +3.6
    Same report last year
    16.8M
    History used
    1,735 days
    2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M2025-08-15: 41.8M2025-08-29: 43.2M2025-09-15: 44.4M
    the 15 Sep 2025 report24 earlier reportsnormal: 21.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  26. 12 Aug 2025Short interest and volume change

    had 39.8M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year.

    Same report last year: 17.4M; its normal report is 18.3M.

    See the evidence
    This period
    39.8M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    18.3M
    Typical spread (median absolute deviation)
    1.9M
    How far from its usual level
    +7.5
    Same report last year
    17.4M
    History used
    1,689 days
    2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M2025-07-31: 39.8M
    the 31 Jul 2025 report24 earlier reportsnormal: 18.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 12 Aug 2025Financials change

    reported revenue of $17.1M for the quarter ended 30 Jun 2025, 2.3× the same quarter last year.

    Same quarter last year: $7.3M; its normal quarter is $7.0M.

    See the evidence
    This period
    $17.1M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $7.0M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    +3.3
    Same quarter last year
    $7.3M
    History used
    1,917 days
    2023-06-30: $10.1M2023-09-30: $6.6M2023-12-31: $9.2M2024-03-31: $10.0M2024-06-30: $7.3M2024-09-30: $6.5M2024-12-31: $5.0M2025-03-31: $4.2M2025-06-30: $17.1M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $7.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 25 Jul 2025Short interest and volume change

    had 35.7M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

    Same report last year: 17.8M; its normal report is 18.0M.

    See the evidence
    This period
    35.7M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    18.0M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +6.6
    Same report last year
    17.8M
    History used
    1,673 days
    2024-07-15: 17.8M2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M2025-06-30: 30.4M2025-07-15: 35.7M
    the 15 Jul 2025 report24 earlier reportsnormal: 18.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 26 Jun 2025Short interest and volume change

    had 26.5M shares sold short in the 13 Jun 2025 report, 1.3× the same report last year.

    Same report last year: 19.7M; its normal report is 18.0M.

    See the evidence
    This period
    26.5M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    18.0M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.7
    Same report last year
    19.7M
    History used
    1,641 days
    2024-06-14: 19.7M2024-06-28: 18.8M2024-07-15: 17.8M2024-07-31: 17.4M2024-08-15: 18.2M2024-08-30: 17.6M2024-09-13: 16.8M2024-09-30: 17.1M2024-10-15: 17.4M2024-10-31: 16.6M2024-11-15: 15.9M2024-11-29: 16.3M2024-12-13: 15.9M2024-12-31: 16.6M2025-01-15: 17.3M2025-01-31: 18.4M2025-02-14: 20.1M2025-02-28: 19.9M2025-03-14: 22.8M2025-03-31: 23.6M2025-04-15: 23.8M2025-04-30: 23.0M2025-05-15: 22.5M2025-05-30: 22.8M2025-06-13: 26.5M
    the 13 Jun 2025 report24 earlier reportsnormal: 18.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 12 Mar 2025Insiders record

    Thermopylae Holdings Ltd. (ten percent owner) bought 343,631 shares of ABCL ($742,243) (dated 11 Mar 2025)

  31. 11 Mar 2025Insiders record

    Montalbano John S. (director) bought 25,000 shares of ABCL ($57,500) (dated 10 Mar 2025)

  32. 8 Mar 2025Insiders record

    Montalbano John S. (director) bought 60,000 shares of ABCL ($140,400) (dated 7 Mar 2025)

  33. 30 Aug 2024Insiders record

    Thermopylae Holdings Ltd. (ten percent owner) bought 283,516 shares of ABCL ($739,977) (dated 29 Aug 2024)

  34. 23 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 23 Feb 2024Filings record

    Director or officer change

  36. 9 Nov 2023Insiders record

    Montalbano John S. (director) bought 30,000 shares of ABCL ($137,400) (dated 8 Nov 2023)

  37. 27 Sep 2023Insiders record

    Hayden Michael R (director) bought 20,000 shares of ABCL ($98,200) (dated 26 Sep 2023)

  38. 15 Sep 2023Insiders record

    Lecault Veronique (Chief Operating Officer) bought 20,000 shares of ABCL ($103,800) (dated 14 Sep 2023)

  39. 10 Aug 2023Insiders record

    Hayden Michael R (director) bought 30,000 shares of ABCL ($177,000) (dated 9 Aug 2023)

  40. 27 May 2023Insiders record

    Thermopylae Holdings Ltd. (ten percent owner) bought 153,000 shares of ABCL ($997,560) (dated 26 May 2023)

Showing the newest 40 of 93 entries; narrow the window or the kind of data to see older ones.

Not listed: 75 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001703057
Ticker
ABCL
Domain
abcellera.com
Hq location
A1|VANCOUVER|V5Y 1 (1 unverified)
Name
AbCellera Biologics Inc., EX-21.1
Uei
D3LSBFZ6MXE3
Wikidata
Q30271491
Wikipedia
AbCellera
  • SEC Form 13F institutional holdings4 records, 216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)84 records5 Apr 2017 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)423 data points31 Dec 2018 to 4 Nov 2026
  • SEC Form 4 insider transactions49 records, 136 data points17 Dec 2020 to 13 Nov 2026
  • FINRA short interest (twice monthly)422 data points15 Dec 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2986 data points11 Dec 2020 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 30 data points12 Feb 2018 to 29 Feb 2024
  • Wikipedia pageviews2471 data points16 Feb 2020 to 21 Nov 2026